8-K: Zomedica Reports Record Q1 2026 Revenue of $8.8 Million

Zomedica achieved record first-quarter revenue of $8.8 million, marking 35% year-over-year growth and its 21st consecutive quarter of record revenue.

Summary

• Reported Q1 2026 revenue of $8.8 million, a 35% increase compared to $6.5 million in Q1 2025.
• Achieved 21st consecutive quarter of record year-over-year revenue.
• Diagnostics segment revenue grew 73% year-over-year to $1.0 million.
• Development Services segment contributed $2.0 million in revenue.
• Operating expenses (excluding prior-year impairment) decreased 21% to $10.4 million.
• Cash burn reduced by 15% to $5.7 million compared to Q1 2025.
• Maintained a strong liquidity position with $47.5 million in cash and available-for-sale securities.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong report, characterized by consistent revenue growth, disciplined expense management, and a clear strategy to improve operational efficiency and cash flow.

Positives

• 35% year-over-year revenue growth, reaching a record $8.8 million for the first quarter.
• Adjusted Non-GAAP EBITDA loss improved by 58% to $2.4 million.
• Operating expenses decreased by $2.7 million (21%) compared to Q1 2025.
• Successful launch of AI-enabled TRUVIEW platform and new strategic collaboration with Boehringer Ingelheim.
• Development Services segment continues to provide a new, scalable revenue stream ($2.0 million in Q1).
• Cash burn reduction of $1.1 million demonstrates improved operational efficiency.

Negatives

• Gross margin of 62% reflects product mix and costs associated with new product manufacturing.
• International sales remained flat compared to Q1 2025.
• Net loss of $4.5 million, though significantly improved from the prior year.
• Capital revenues remained consistent with Q1 2025, showing no growth in that specific category.

Risks

• Uncertainty regarding the long-term revenue sustainability of the new Development Services segment.
• Supply chain risks, particularly regarding potential tariff changes.
• Dependence on strategic partners to fulfill commercial and manufacturing obligations.
• Market competition and the ability to maintain veterinary adoption of capital equipment.
• Complexity of accounting estimates and potential for future impairment charges if market capitalization declines.

Future Outlook

Management expects margins to improve throughout the year as seasonal dynamics normalize and operating efficiencies take effect. The company anticipates quarterly reductions in cash burn for the remainder of 2026 and expects the Development Services segment to continue contributing to operating leverage.

Management Comments

• Delivering 35% growth and achieving record year-over-year revenue for the 21st consecutive quarter reflects the consistency of our execution.
• Surpassing $8 million in first quarter revenue for the first time is a meaningful milestone.
• We expect the first quarter's cash burn to be the highest of the year followed by quarterly reductions in cash burn throughout the year.

Industry Context

StockSavvy.ai notes that Zomedica is successfully pivoting from a pure-play diagnostic company to a diversified animal health platform. The growth in the Development Services segment mirrors a broader industry trend where veterinary companies leverage their R&D and manufacturing infrastructure to provide contract services to human and animal health peers, effectively diversifying revenue streams beyond traditional veterinary product sales.

Comparison to Industry Standards

• Revenue growth of 35% significantly outpaces typical mid-single-digit growth seen in mature animal health incumbents like Zoetis or IDEXX.
• Gross margin of 62% is competitive within the veterinary device space, though slightly below the 65-70% range often seen in high-margin diagnostic consumables.
• The company's focus on 'Zero Touch' and AI-enabled diagnostics aligns with current industry shifts toward digital pathology and remote monitoring.

Stakeholder Impact

• Shareholders: Positive impact due to revenue growth and reduced cash burn.
• Customers: Benefit from expanded diagnostic and therapeutic product offerings.
• Employees: Continued focus on operational efficiency may imply ongoing cost-discipline measures.

Next Steps

• Host the Fifth Friday at Four Webinar on May 29, 2026.
• Continue scaling the Development Services segment.
• Execute on the Boehringer Ingelheim collaboration for PPID testing.

Key Dates

Recommendation

The company is demonstrating consistent top-line growth, successful integration of new business segments, and a clear path toward reducing cash burn, making it an attractive prospect for growth-oriented investors in the animal health sector.

Keywords

Zomedica, veterinary diagnostics, animal health, TRUFORMA, PulseVet, equine healthcare, point-of-care diagnostics, Q1 2026 earnings